Dilemmas & challenges in the management of generalized tonic-clonic seizures: Can we do more?
05 May 2017
At a recent satellite symposium convened during the 11th Asian & Oceanian Epilepsy Congress (AOEC) in Hong Kong, experts on convulsive epilepsy discussed the dilemmas and challenges currently encountered in the diagnosis and subsequent management of generalized tonic-clonic (GTC) seizures. The symposium was chaired by Dr Ada Yung (Associate Consultant, Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong), and it focused in particular on perampanel, the first and only approved non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist. Perampanel is approved for the management of patients experiencing partial-onset seizures, with or without secondarily generalized seizures, in seven countries across Asia and for primary GTC seizures in four Asian countries, with more approvals expected later this year.